A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2017
At a glance
- Drugs Tazarotene/ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Valeant Pharmaceuticals International
- 10 Jan 2017 Primary endpoint has been met. (Treatment success rate), as reported by a Valeant Pharmaceuticals International Media Release.
- 10 Jan 2017 Results published in the Valeant Pharmaceuticals International Media Release
- 08 Dec 2016 According to a Valeant Pharmaceuticals media release, company expects to have data from this study in 2017.